Novo Nordisk EBITDA Margin 2012-2026 | NVO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Novo Nordisk (NVO) over the last 10 years. The current EBITDA margin for Novo Nordisk as of March 31, 2026 is
Unlock Macrotrends Premium
Start 7-Day Free Trial
Novo Nordisk EBITDA Margin Historical Data
Date
TTM Revenue
TTM EBITDA
EBITDA Margin
2026-03-31
$50.94B
$26.53B
52.09%
2025-12-31
$46.79B
$22.66B
48.42%
2025-09-30
$46.71B
$22.81B
48.82%
2025-06-30
$45.48B
$23.18B
50.97%
2025-03-31
$43.61B
$22.33B
51.21%
2024-12-31
$42.11B
$21.38B
50.77%
2024-09-30
$39.37B
$19.72B
50.07%
2024-06-30
$37.44B
$18.67B
49.88%
2024-03-31
$35.55B
$17.47B
49.15%
2023-12-31
$33.72B
$16.26B
48.22%
2023-09-30
$30.85B
$14.63B
47.41%
2023-06-30
$28.44B
$13.31B
46.80%
2023-03-31
$26.41B
$12.35B
46.77%
2022-12-31
$25.06B
$11.64B
46.44%
2022-09-30
$24.32B
$11.39B
46.83%
2022-06-30
$23.81B
$11.03B
46.34%
2022-03-31
$23.26B
$10.77B
46.32%
2021-12-31
$22.40B
$10.29B
45.93%
2021-09-30
$21.64B
$9.89B
45.71%
2021-06-30
$20.85B
$9.64B
46.21%
2021-03-31
$19.93B
$9.26B
46.46%
2020-12-31
$19.45B
$9.17B
47.17%
2020-09-30
$19.09B
$9.11B
47.73%
2020-06-30
$18.74B
$8.98B
47.91%
2020-03-31
$18.84B
$8.96B
47.55%
2019-12-31
$18.29B
$8.72B
47.65%
2019-09-30
$17.43B
$8.37B
48.03%
2019-06-30
$17.25B
$8.09B
46.93%
2019-03-31
$17.11B
$7.98B
46.61%
2018-12-31
$17.10B
$7.82B
45.76%
2018-09-30
$17.61B
$7.95B
45.15%
2018-06-30
$17.49B
$8.02B
45.89%
2018-03-31
$17.33B
$8.06B
46.51%
2017-12-31
$16.97B
$7.92B
46.68%
2017-09-30
$16.81B
$7.96B
47.34%
2017-06-30
$16.73B
$7.90B
47.19%
2017-03-31
$16.67B
$7.80B
46.77%
2016-12-31
$16.61B
$7.67B
46.19%
2016-09-30
$16.56B
$7.67B
46.28%
2016-06-30
$16.43B
$7.58B
46.12%
2016-03-31
$16.26B
$7.51B
46.18%
2015-12-31
$16.06B
$7.80B
48.56%
2015-09-30
$15.99B
$7.57B
47.36%
2015-06-30
$15.95B
$7.21B
45.23%
2015-03-31
$15.92B
$6.88B
43.20%
2014-12-31
$15.83B
$6.15B
38.84%
2014-09-30
$15.63B
$5.95B
38.08%
2014-06-30
$15.31B
$5.85B
38.18%
2014-03-31
$15.08B
$5.75B
38.09%
2013-12-31
$14.89B
$5.61B
37.68%
2013-09-30
$14.58B
$5.59B
38.30%
2013-06-30
$14.27B
$5.49B
38.45%
2013-03-31
$13.89B
$5.31B
38.19%
2012-12-31
$13.48B
$5.09B
37.77%
2012-09-30
$13.04B
$4.45B
34.08%
2012-06-30
$12.80B
$4.23B
33.08%
2012-03-31
$12.52B
$4.07B
32.53%
2011-12-31
$12.27B
$4.05B
33.02%
2011-09-30
$12.04B
$4.41B
36.67%
2011-06-30
$11.85B
$4.49B
37.88%
2011-03-31
$11.48B
$4.34B
37.82%
2010-12-31
$11.06B
$4.03B
36.43%
2010-09-30
$10.66B
$4.00B
37.50%
2010-06-30
$10.24B
$3.62B
35.36%
2010-03-31
$9.90B
$3.35B
33.87%
2009-12-31
$9.67B
$3.25B
33.62%
2009-09-30
$9.31B
$3.25B
34.85%
2009-06-30
$9.10B
$3.10B
34.06%
2009-03-31
$8.21B
$2.09B
25.44%
2008-12-31
$8.12B
$1.95B
24.05%
2008-09-30
$8.02B
$1.73B
21.54%
2008-06-30
$7.69B
$1.56B
20.24%
2008-03-31
$8.11B
$2.32B
28.54%
2007-12-31
$7.71B
$2.15B
27.88%
2007-09-30
$7.59B
$2.28B
30.10%
2007-06-30
$7.24B
$2.17B
29.98%
2007-03-31
$6.44B
$1.59B
24.63%
2006-12-31
$6.16B
$1.50B
24.28%
2006-09-30
$5.81B
$1.28B
22.05%
2006-06-30
$5.73B
$1.35B
23.53%
2006-03-31
$6.02B
$1.85B
30.74%
2005-12-31
$5.86B
$1.83B
31.18%
2005-09-30
$5.61B
$1.02B
18.15%
2005-06-30
$5.36B
$0.88B
16.45%
2005-03-31
$5.13B
$0.78B
15.12%
2004-12-31
$4.96B
$1.49B
30.14%
2004-09-30
$4.70B
$1.98B
42.15%
2004-06-30
$4.46B
$1.89B
42.37%
2004-03-31
$4.27B
$1.79B
41.95%
2003-12-31
$4.06B
$0.98B
24.24%
2003-09-30
$4.13B
$0.83B
20.12%
2003-06-30
$3.97B
$0.82B
20.56%
2003-03-31
$3.78B
$0.78B
20.64%
2002-12-31
$3.54B
$0.70B
19.77%
2002-09-30
$3.06B
$-0.96B
-31.34%
2002-06-30
$2.91B
$-0.48B
-16.41%
2002-03-31
$2.80B
$0.03B
1.07%
2001-12-31
$2.82B
$0.56B
19.77%
2001-09-30
$2.49B
$0.33B
13.40%
2001-06-30
$2.43B
$0.30B
12.16%
2001-03-31
$2.53B
$0.42B
16.44%
2000-12-31
$2.59B
$0.51B
19.85%
2000-09-30
$2.95B
$2.95B
100.00%
2000-06-30
$3.09B
$3.09B
100.00%
2000-03-31
$3.02B
$3.02B
100.00%
1999-12-31
$2.96B
$2.96B
100.00%
1999-09-30
$2.94B
$2.94B
100.00%
1999-06-30
$2.82B
$2.82B
100.00%
1999-03-31
$2.75B
$2.75B
100.00%
1998-12-31
$2.68B
$2.68B
100.00%
1998-09-30
$2.60B
$2.60B
100.00%
1998-06-30
$2.65B
$2.65B
100.00%
1998-03-31
$2.61B
$2.61B
100.00%
1997-12-31
$2.58B
$2.58B
100.00%
1997-09-30
$2.60B
$2.60B
100.00%
1997-06-30
$2.53B
$2.53B
100.00%
1997-03-31
$2.52B
$2.52B
100.00%
1996-12-31
$2.56B
$2.56B
100.00%
1996-09-30
$2.48B
$2.48B
100.00%
1996-06-30
$2.45B
$2.45B
100.00%
1996-03-31
$2.48B
$2.48B
100.00%
1995-12-31
$2.46B
$2.46B
100.00%
1995-09-30
$2.43B
$2.43B
100.00%
1995-06-30
$2.36B
$2.36B
100.00%
1995-03-31
$2.25B
$2.25B
100.00%
1994-12-31
$2.14B
$2.14B
100.00%
1994-09-30
$2.04B
$2.04B
100.00%
1994-06-30
$1.96B
$1.96B
100.00%
1994-03-31
$1.87B
$1.87B
100.00%
1993-12-31
$1.84B
$1.84B
100.00%
1993-06-30
$1.30B
$1.30B
100.00%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $167.527B
$46.797B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
